药物信息为Chenodal 250 mg (chenodiol tablets) (Manchester Pharmaceuticals Inc.): SPECIAL NOTE
- SPECIAL NOTE
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- Evaluation of Surgical Risk
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- 外部链接相关的Chenodal 250 mg (chenodiol tablets) (Manchester Pharmaceuticals Inc.)
- Because of the potential hepatoxicity of Chenodal, poor response rate in some subgroups of Chenodal treated patients, and an increased rate of a need for cholecystectomy in other Chenodal treated subgroups, Chenodal is not an appropriate treatment for many patients with gallstones. Chenodal should be reserved for carefully selected patients and treatment must be accompanied by systematic monitoring for liver function alterations. Aspects of patient selection, response rates and risks versus benefits are given in the insert.
- Drug Information Provided by National Library of Medicine (NLM).
这个站点被设计主要作为提示系统供合格的医师和其他医疗专家使用。 通过使用这个站点您了解并且接受DiagnosisPro.com不会使用作为一个诊断决策系统，并且不能使用做一个临床诊断或替换或者否决一位被准许的医疗保健专家的评断或临床诊断 (充分的使用条款). 我们遵循健康网络基金会的 医学和健康网站的行为准则. 点击这里核实
© 2012 MedTech USA, Inc. (最后更新在05/25/12)
